Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Inclusion Criteria:

Males and females aged ≥18 years;
ECOG performance status (PS) 0-2;
Diagnosis of systemic AL amyloidosis (subjects with non-AL amyloidosis are not eligible);
Received at least one prior systemic therapy, which may include stem cell transplant, for AL amyloidosis;
Have adequate organ function;
Ability to understand and willingness to sign informed consent prior to initiation of any study procedures.

Exclusion Criteria:

Secondary or familial amyloidosis;
Life expectancy of < 3 months;
Symptomatic multiple myeloma;
Hypersensitivities to other monoclonal antibodies;
Known HIV infection;
Women who are lactating;
Any other condition or prior therapy, which in the opinion of the PI, would make the subject unsuitable for the study.